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Hepatitis C (HCV) is on the rise among women of childbearing age as well as young children in the USA, suggesting increasing mother-to-child transmission (MTCT) of the virus. 1 Epidemiologic data demonstrates that HCV is now a bimodal disease. In addition to the originally identified birth cohort , a second spike in prevalence is recognized in individuals between the ages of 20 years and 35 years, driven primarily by the concurrent rise in injectable opioid abuse, as well as ongoing challenges to HCV prevention and access to HCV direct-acting antiviral (DAA) treatment. 2, 3 This younger demographic includes women of reproductive age in the USA where the number of exposed women doubled between 2006 and 2014. As a result, rates of HCV among pregnant women at delivery increased 89% between 2009 and 2014. HCV infection in infants and children has also increased, presumably as a result of MTCT of the virus. 4, 5 In reaction to the increasing prevalence of HCV among women and children, the American Association For The Study of Liver Diseases-Infectious Diseases Society of America (AASLD-IDSA) guidelines recently updated their recommendations to include universal, rather than risk-based, HCV screening among pregnant women. 6 As expected, more women are now being diagnosed with HCV in pregnancy. This poses a clinical dilemma as therapeutic options to interrupt MTCT are limited. Moreover, liver and obstetric national societal guidelines discourage the use of antiviral HCV therapy during pregnancy despite existing algorithms for the use of antiviral therapy to disrupt transmission in other viral infections such as hepatitis B virus (HBV) and HIV. Still, the use of DAA therapy during pregnancy is potentially attractive on many levels.
Here, we discuss several reasons to consider DAA therapy during pregnancy.
( Nationally, HCV rates during pregnancy have increased by significantly more than those of HBV or HIV and national birth certificate data have demonstrated an increase of 68% in the proportion of infants born to mothers with HCV. 8, 9 Given these increases in HCV, there will be more women potentially seeking treatment for HCV during pregnancy.
(2) Identification of perinatally transmitted HCV is poor as children born to mothers infected with HCV are rarely tested. Even if these estimates of MTCT are correct, transmission rates of HCV are in the same range as the rate of MTCT in highly viremic women with HBV (despite birth dose HBV vaccination and hepatitis B immunoglobulin). 13 Here, guidelines universally recommend antiviral therapy in the third trimester purely to disrupt the risk of MTCT of HBV. This short course of therapy offers no benefit to the mother and may even increase the risk of postpartum flare when therapy is discontinued. 14 Treating HCV during pregnancy would not only cure disease in the mother, but also potentially lower the risk of MTCT.
(3) Pediatric HCV has increased in concert with the increase of maternal HCV.
Childhood HCV is increasing with MTCT as the leading cause for pediatric infection. During the past decade, the prevalence of HCV infection in young children throughout the USA has increased more than three-fold, increasing from 0.5% to 1.6%. 1 Also during this time, the rate of infant HCV referrals in parts of Appalachia (southern Ohio and western Pennsylvania) has increased more than four-fold. Furthermore, between 2006 and 2012, the number of hospitalizations of children infected with HCV increased 37%, to 3.7 per 10,000 admissions. 15, 16 (4) Treatment during pregnancy is an attractive option from the perspective of both mother and child.
Unfortunately, even after appropriate diagnosis, many persons in need of therapy are unable to receive it. While specific data on pediatric HCV are limited, overall linkage rates are poor. In a single center in Tennessee (representative of among the most affected demographics) only 60% of those identified with HCV were able to begin treatment, while in Philadelphia only 62% were able to follow up with an appropriate subspecialist for treatment. 17, 18 Although all oral treatment options are expanding to the pediatric population, identification and linkage to care and timing of therapy remain problematic. Untreated, these children can both be stigmatized as well as at risk for viral transmission to others. Furthermore, a recent study by the UK HCV Research Group found that children who are infected with HCV through MTCT developed cirrhosis at an earlier age than children who acquired infection through other routes during childhood, and are also at risk of acquiring hepatocellular carcinoma, 19 increasing the importance of interrupting MTCT. Moreover, when surveyed, the majority of women with a history of HCV appear to be interested in HCV treatment during pregnancy if it could decrease MTCT. 20 Although those opposed to treatment during pregnancy advocate for treatment postdelivery, linkage to care postdelivery is difficult. Pregnancy offers a period when high-risk women have access to health care. Postpartum, women (and infants) are often lost to follow up. 12 Furthermore, there are significant gaps in the cascade of care at the linkage phase, even in highly specialized settings such as obstetric clinics for women with substance use disorders. 21 Treatment of HCV during pregnancy would reduce loss to follow up by treating women at a time when they are engaged in their pregnancy care.
Despite these reasons to consider treatment during pregnancy, many providers are hesitant, citing potential risk to the infant of drug exposure and insufficient benefit to the mother to outweigh these risks. However, in vitro studies suggest DAA drugs are safe during pregnancy. 22 Sofosbuvir, a main stay of multiple DAA regimens, appears to have a favorable pharmacokinetic profile that should not be affected by pregnancy and no negative pregnancy outcomes have been reported in a registry of the European Medical Agency. 23 Although for US Food and Drug Administration (FDA) approval, evaluation of medications in pregnancy is not required (and most medications are used 'off-label' during pregnancy), preclinical studies of pregnant rats and rabbits showed there were no safety concerns for antenatal administration, which was what informed the pregnancy category B designation of many DAA regimens. Since 2014, other DAAs, such as sofosbuvir and velpatasvir, and glecaprevir/pibrentasvir, have been approved and none of these medications have been known to cause any fetal toxicities in preclinical studies except when the dose was high enough to produce maternal toxicity as well. [24] [25] [26] Interestingly providers are generally comfortable with treating HBV during pregnancy, despite arguably the lesser benefit to the mother and journals.sagepub.com/home/tai 3 potential risks of drug exposure to the infant, even though HBV treatment does not provide cure and leads to a risk of HBV flare following discontinuation of HBV therapy postpartum. 27 Studies are underway to confirm the efficacy of DAA therapy given during pregnancy, both in curing the mother and disrupting MTCT. Registries and clinical trials to evaluate further the use of DAAs in the pregnancy period will be important to further clarify safety and efficacy. Future studies will also need to identify maternal and fetal factors that may make treatment during pregnancy optimal over postpartum therapy, which take into consideration the safety of DAA treatments, an individual's particular risk of loss to follow up postdelivery, and the likelihood of potential treatment of their children in the event of MTCT. Lastly, engaging the obstetrician and patient in this conversation is vital. However there is no conversation if there are no options.
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